Epidermolysis Bullosa (Dermatology) - Drugs In Development, 2021

July 2021 | 169 pages | ID: E66FFCD2FB2FEN
Global Markets Direct

Abstracts

Epidermolysis Bullosa (Dermatology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Drugs In Development, 2021, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 10, 2, 2, 13, 8 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Epidermolysis Bullosa - Overview
Epidermolysis Bullosa - Therapeutics Development
Epidermolysis Bullosa - Therapeutics Assessment
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Epidermolysis Bullosa - Drug Profiles
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Epidermolysis Bullosa, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, 2021
Epidermolysis Bullosa - Pipeline by Aegle Therapeutics Corp, 2021
Epidermolysis Bullosa - Pipeline by Almirall SA, 2021
Epidermolysis Bullosa - Pipeline by Amniotics AB, 2021
Epidermolysis Bullosa - Pipeline by Amryt Pharma Plc, 2021
Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, 2021
Epidermolysis Bullosa - Pipeline by Berg LLC, 2021
Epidermolysis Bullosa - Pipeline by BioVec Pharma Inc, 2021
Epidermolysis Bullosa - Pipeline by Castle Creek Biosciences Inc, 2021
Epidermolysis Bullosa - Pipeline by Celularity Inc, 2021
Epidermolysis Bullosa - Pipeline by Constant Therapeutics LLC, 2021
Epidermolysis Bullosa - Pipeline by CSA Biotechnologies LLC, 2021
Epidermolysis Bullosa - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Epidermolysis Bullosa - Pipeline by Eloxx Pharmaceuticals Inc, 2021
Epidermolysis Bullosa - Pipeline by Energenesis Biomedical Co Ltd, 2021
Epidermolysis Bullosa - Pipeline by FIBRX Derm Inc, 2021
Epidermolysis Bullosa - Pipeline by Holostem Terapie Avanzate SRL, 2021
Epidermolysis Bullosa - Pipeline by Immusoft Corp, 2021
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, 2021
Epidermolysis Bullosa - Pipeline by Kang Stem Biotech Co Ltd, 2021
Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, 2021
Epidermolysis Bullosa - Pipeline by LambdaGen Therapeutics, 2021
Epidermolysis Bullosa - Pipeline by Mariposa Therapeutics Ltd, 2021
Epidermolysis Bullosa - Pipeline by OTR3 SAS, 2021
Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, 2021
Epidermolysis Bullosa - Pipeline by Panag Pharma Inc, 2021
Epidermolysis Bullosa - Pipeline by Phoenix Tissue Repair Inc, 2021
Epidermolysis Bullosa - Pipeline by Quoin Pharmaceuticals Ltd, 2021
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, 2021
Epidermolysis Bullosa - Pipeline by Relief Therapeutics Holding AG, 2021
Epidermolysis Bullosa - Pipeline by RHEACELL GmbH & Co KG, 2021
Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, 2021
Epidermolysis Bullosa - Pipeline by StemRIM Inc, 2021
Epidermolysis Bullosa - Pipeline by Therapicon Srl, 2021
Epidermolysis Bullosa - Pipeline by TWi Biotechnology Inc, 2021
Epidermolysis Bullosa - Pipeline by Vera Therapeutics Inc, 2021
Epidermolysis Bullosa - Pipeline by Wings Therapeutics, 2021
Epidermolysis Bullosa - Dormant Projects, 2021
Epidermolysis Bullosa - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Epidermolysis Bullosa, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021